MedTrace Logo

A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)

NCT00520572 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 385

Last updated 2013-02-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid arthritis with regard to signs and symptoms and to determine what dose is favourable over a 6-month treatment period. Patients will receive background treatment with either Methotrexate or Sulphasalazine

Conditions

Interventions

DRUG

AZD9056

DRUG

Etanercept

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Edward Keystone, MD, FRCPC · MOUNT SINAI HOSPITAL

  • Zoltan Koroknai, MD, D.E.A.A. · Omnicare Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Completion
2009-03-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • Czechia
  • France
  • Mexico
  • Poland
  • Romania
  • Russia
  • Slovakia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520572 on ClinicalTrials.gov